No Data
Tailin Bioengineering to Buy Back Up to 40 Million Yuan Worth of Shares
TAILIN (300813.SZ): plans to propose an employee stock ownership plan in 2025.
On March 11, Gelonghui reported that TAILIN (300813.SZ) announced the employee stock ownership plan for 2025. This employee stock ownership plan will be obtained and held through non-trade transfer and other legal methods as approved by the company's shareholders' meeting. The total number of shares will not exceed 1.208 million shares, accounting for 1.00% of the company's current total share capital, with the specific number of shares determined based on the actual funding situation. After the shareholders' meeting approval, this employee stock ownership plan will acquire and hold the symbol Stocks through non-trade transfers and other legally permitted methods. This ownership plan will transfer the symbol.
TAILIN (300813.SZ): plans to repurchase shares for 20 million yuan to -40 million yuan.
Gelonghui, on March 11, announced that TAILIN (300813.SZ) plans to use a total of no less than 20 million yuan and no more than 40 million yuan for the repurchase of shares, with the specific total amount of funds for repurchase to be based on the actual amount used. Based on the repurchase cap of 40 million yuan and a maximum repurchase price of 27.56 yuan per share, the number of shares intended for repurchase is approximately 1.451378 million shares, not exceeding 1.20% of the company's currently issued total share capital; based on the minimum total amount of 20 million yuan and a maximum repurchase price of 27.56 yuan per share.
After on-site inspections of the sixth company this month, TAILIN and the Director received a warning letter | Quick read of the announcement.
① During the on-site inspection, issues such as insufficient production capacity for some public fundraising projects were discovered, resulting in TAILIN and related responsible persons receiving a warning letter from the Zhejiang Securities Regulatory Bureau; ② At the end of 2024, TAILIN had previously postponed the public fundraising project "Cell Therapy Industrial Equipment Manufacturing Base Project" by six months; ③ This is the sixth listed company warned after being inspected by the local Securities Regulatory Bureau this month.
TAILIN (300813.SZ) received a warning letter from the Zhejiang Securities Regulatory Bureau.
TAILIN Bio (300813.SZ) announced that the company recently received a notice from the Zhejiang Securities Regulatory Bureau regarding Zhejiang TAILIN...
TAILIN (300813.SZ): Plans to postpone the "Cell Therapy Industrialization Equipment Manufacturing Base Project" until June 30, 2025.
Gelonghui, December 31丨TAILIN (300813.SZ) announced that the company will hold the fifth meeting of the fourth Board of Directors and the fifth meeting of the fourth Supervisory Board on December 31, 2024. The proposal concerning the extension of the fundraising for the issuance of Convertible Bonds to unspecified entities was reviewed and approved. Under the condition that the investment project主体, implementation location, investment purpose, and investment scale do not change, based on the current actual construction progress of the fundraising investment project, the fundraising for the Convertible Bonds will be allocated to the "Cell Therapy Industrialization Equipment Manufacturing Base Project" to reach the predetermined usable state.
Optimistic Investors Push Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) Shares Up 28% But Growth Is Lacking
